◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PHG

Koninklijke Philips NV ADR (PHG) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-19

Koninklijke Philips NV ADR (PHG) operates in the MEDICAL DEVICES industry and is headquartered in Amsterdam, Netherlands with about 63,670 employees. Its market capitalization is roughly $24 billion. In the fiscal year ended 2025-12-31, PHG reported €17.8B in revenue and €895M in net income.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments.

Interactive charts & full statements → Open the PHG valuation workbench →

PHG Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	€17.7B	€17.8B	€18.0B	€18.2B	€17.8B	€17.2B	€17.3B	€17.1B	€18.1B	€17.8B	€24.5B	€24.2B	€21.4B	€23.3B	€24.8B	€22.6B	€25.4B	€23.2B	€26.4B	€26.8B	€27.0B
Gross Profit	€8.1B	€8.1B	€7.8B	€7.4B	€7.2B	€7.2B	€7.9B	€7.9B	€8.6B	€8.2B	€10.6B	€9.9B	€8.2B	€9.7B	€9.4B	€8.6B	€9.5B	€8.1B	€8.5B	€9.2B	€8.3B
Gross Margin %	45.9%	45.2%	43.1%	41.0%	40.4%	41.8%	45.7%	46.4%	47.2%	46.0%	43.3%	40.6%	38.4%	41.5%	38.0%	38.3%	37.5%	34.8%	32.1%	34.2%	30.8%
Operating Income (EBIT)	€1.7B	€1.4B	€529M	(€115M)	(€1.5B)	€553M	€1.3B	€1.4B	€1.7B	€1.5B	€1.9B	€992M	€486M	€2.0B	€1.0B	(€269M)	€2.1B	€614M	€54M	€1.9B	€1.2B
Operating Margin %	9.7%	8.0%	2.9%	-0.6%	-8.6%	3.2%	7.3%	8.0%	9.5%	8.5%	7.7%	4.1%	2.3%	8.5%	4.2%	-1.2%	8.1%	2.6%	0.2%	6.9%	4.4%
Net Income	€1.1B	€895M	(€702M)	(€466M)	(€1.6B)	€3.3B	€1.2B	€1.2B	€1.1B	€1.7B	€1.4B	€645M	€415M	€1.2B	€226M	(€1.3B)	€1.4B	€410M	(€92M)	€4.2B	€5.4B
Net Margin %	6.3%	5.0%	-3.9%	-2.6%	-9.0%	19.4%	6.9%	6.8%	6.0%	9.3%	5.9%	2.7%	1.9%	5.0%	0.9%	-5.7%	5.7%	1.8%	-0.4%	15.6%	20.0%
EBITDA	—	€2.6B	€1.8B	€1.0B	€115M	€2.0B	€2.8B	€2.6B	€2.8B	€2.6B	€2.4B	€1.8B	€1.8B	€3.1B	€1.9B	€1.0B	€3.6B	€2.3B	€656M	€2.7B	€2.0B
Earnings Per Share (EPS)	€1.16	€0.93	€-0.75	€-0.49	€-1.69	€3.49	€1.24	€1.20	€1.09	€1.64	€1.46	€0.66	€0.42	€1.19	€0.23	€-1.27	€1.43	€0.41	€-0.09	€3.57	€4.27
Shares Outstanding (M)	—	963M	933M	949M	952M	950M	958M	973M	997M	1,007M	990M	984M	983M	983M	988M	1,020M	1,010M	990M	1,062M	1,170M	1,261M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHG Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	€4.4B	€3.9B	€5.1B	€4.3B	€4.3B	€4.1B	€5.0B	€4.4B	€4.5B
Gross Profit	€2.1B	€1.8B	€2.3B	€1.9B	€2.0B	€1.8B	€2.0B	€2.0B	€2.0B
Gross Margin %	49.3%	45.2%	44.9%	44.4%	46.4%	45.1%	38.9%	45.8%	44.6%
Operating Income (EBIT)	€610M	€241M	€540M	€330M	€400M	€154M	€199M	€337M	€816M
Operating Margin %	14.0%	6.2%	10.6%	7.7%	9.2%	3.8%	4.0%	7.7%	18.3%
Net Income	€384M	€151M	€395M	€184M	€240M	€76M	(€335M)	€181M	€451M
Net Margin %	8.8%	3.9%	7.8%	4.3%	5.5%	1.9%	-6.6%	4.1%	10.1%
EBITDA	—	€538M	€853M	€635M	€683M	€462M	€546M	€351M	€597M
Earnings Per Share (EPS)	€0.40	€0.16	€0.41	€0.19	€0.25	€0.08	€-0.36	€0.20	€0.48
Shares Outstanding (M)	—	969M	966M	964M	957M	938M	929M	913M	942M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHG Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	€2.3B	€1.2B	€1.7B	€2.3B	(€173M)	€1.6B	€2.8B	€2.0B	€1.8B	€1.9B	€1.9B	€1.2B	€1.3B	€1.1B	€2.2B	€566M	€2.2B	€1.5B	€1.5B	€1.4B	€854M
Capital Expenditures (CapEx)	—	€269M	€343M	€372M	€806M	€763M	€942M	€1.0B	€843M	€859M	€869M	€957M	€846M	€993M	€1.1B	€841M	€952M	€620M	€892M	€781M	€803M
Free Cash Flow (FCF)	—	€893M	€1.4B	€1.9B	(€979M)	€866M	€1.8B	€1.0B	€937M	€1.0B	€1.0B	€210M	€457M	€145M	€1.1B	(€275M)	€1.2B	€925M	€603M	€588M	€51M
FCF Margin %	—	5.0%	7.5%	10.7%	-5.5%	5.1%	10.6%	5.9%	5.2%	5.7%	4.2%	0.9%	2.1%	0.6%	4.6%	-1.2%	4.7%	4.0%	2.3%	2.2%	0.2%
Dividends Paid	—	€328M	€1M	€2M	€412M	€482M	€1M	€453M	€401M	€384M	€330M	€298M	€292M	€272M	€255M	€259M	€296M	€634M	€698M	€640M	€523M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHG Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	€376M	€191M	€1.4B	€327M	€387M	(€982M)	€1.4B	€274M	€89M
Capital Expenditures (CapEx)	—	€74M	€83M	€68M	€159M	€58M	€506M	€0M	€159M
Free Cash Flow (FCF)	—	€117M	€1.3B	€259M	€228M	(€1.0B)	€871M	€274M	(€70M)
FCF Margin %	—	3.0%	25.7%	6.0%	5.3%	-25.4%	17.3%	6.3%	-1.6%
Dividends Paid	—	—	€328M	€33M	€295M	—	€1M	—	€1M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHG Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	€26.7B	€26.9B	€29.0B	€29.4B	€30.7B	€31.0B	€27.7B	€27.0B	€26.0B	€25.3B	€32.3B	€31.0B	€28.4B	€26.6B	€29.1B	€29.0B	€32.3B	€30.5B	€31.8B	€36.4B	€38.5B
Cash & Cash Equivalents	€1.8B	€2.8B	€2.4B	€1.9B	€1.2B	€2.3B	€3.2B	€1.4B	€1.7B	€1.9B	€2.3B	€1.8B	€1.9B	€2.5B	€3.8B	€3.1B	€5.8B	€4.4B	€3.6B	€8.8B	€6.0B
Total Liabilities	€15.2B	€16.0B	€16.9B	€17.3B	€17.4B	€16.5B	€15.8B	€14.4B	€13.9B	€13.3B	€18.8B	€19.2B	€17.4B	€15.3B	€17.9B	€16.6B	€17.2B	€15.9B	€16.2B	€14.6B	€15.4B
Total Debt (Short + Long-Term)	€7.5B	€8.1B	€6.6B	€6.4B	€7.6B	€6.8B	€6.9B	€4.2B	€4.4B	€3.9B	€5.6B	€5.8B	€4.9B	€5.2B	€5.7B	€4.8B	€5.6B	€5.8B	€5.5B	€4.1B	€4.8B
Total Shareholders' Equity	€11.4B	€11.0B	€12.0B	€12.0B	€13.2B	€14.4B	€11.9B	€12.6B	€12.1B	€12.0B	€12.6B	€11.7B	€10.9B	€11.2B	€11.1B	€12.4B	€15.0B	€14.6B	€15.6B	€21.7B	€23.0B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PHG viewer.

PHG Metric Deep Dives

Other Companies in MEDICAL DEVICES

PEN · Penumbra Inc — $13 billion
SNN · Smith & Nephew SNATS Inc — $12 billion
BIO · Bio-Rad Laboratories Inc — $10 billion
GMED · Globus Medical — $10 billion
BIO.B · Bio-Rad Laboratories Inc — $10 billion
GKOS · Glaukos Corp — $10 billion
BRKR · Bruker Corporation — $9 billion
HAE · Haemonetics Corporation — $5 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← PHEQ All “P” companies PHI →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.